Eylem Seç
Glycoconjugate-Based Vaccines for Chagas Disease
Başlık:
Glycoconjugate-Based Vaccines for Chagas Disease
Yazar:
Zepeda, Brenda Guadalupe, author.
ISBN:
9780438028524
Yazar Ek Girişi:
Fiziksel Tanımlama:
1 electronic resource (116 pages)
Genel Not:
Source: Masters Abstracts International, Volume: 57-06M(E).
Advisors: Igor C. Almeida Committee members: Rosa A. Maldonado; Katja Michael.
Özet:
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. About 6--8 million people are estimated to be infected worldwide. It is a blood borne pathogen and transmitted to humans by the insect vector (kissing bug), blood transfusion, organ transplant, contaminated foods and juices, and by congenital contagion. The chemotherapy is partially effective in chronic phase of the disease, and the drugs cause several side effects. There is no vaccine to prevent or treat Chagas disease. The great majority of experimental vaccines have employed whole parasite extracts, purified or recombinant proteins, synthetic peptides, or DNA; however, most of them provide only partial protection. The goal of this project is to evaluate the effect of an alphaGal-based neoglycoprotein (NGP) vaccine against ChD in the alpha1,3-galactosyltransferase-knockout (alpha1,3-GalT-KO) mice. In our first study, mice were vaccinated with NGP Galalpha(1,3)Galbeta(1,4)GlcNAcalpha-BSA (3 atom spacer, Dextra) and T. cruzi.
-challenged three consecutive times. This study showed that parasitemia is lower after a second and third challenge; however, they were not protected after immunosuppression. In our second study, NGP Galalpha(1,3)Galbeta(1,4)GlcNAcbeta-BSA (KM24b) was combined with LMPLA. This study showed that vaccination with KM24b alone gave much lower survival rate as compared to the previous study using Galalpha(1,3)Galbeta(1,4)GlcNAcbeta-BSA. The differences between the two NGPs are: (a) the anomeric configuration of the reducing-end GlcNAc residue (alpha vs. beta), (b) and length of the spacer (3-atom linker in the Galalpha(1,3)Galbeta(1,4)GlcNAcbeta-BSA vs. 13-atom linker in the KM24b). In our third study, mice were vaccinated with alphaGal-containing NGPs with linkers with distinct length (3-atom vs. 14-atom-linker) and different carrier proteins (BSA or HSA). This study showed that carrier protein and the linker length are crucial parameters to be considered in the design of NGPs to be tested as experimental vaccines for ChD. In our fourth study, the commercial NGP Galalpha(1,3)Galbeta(1,4)GlcNAc-NH-HSA (3 atom-linker) was combined with LMPLA. This study showed that vaccination with NGP Galalpha(1,3)Galbeta(1,4)GlcNAc-NH-HSA (3 atom-linker) alone gave higher survival rate (100%) and higher protection than vaccination with NGP Galalpha(1,3)Galbeta(1,4)GlcNAc-NH-HSA (3 atom-linker) combined with LMPLA. In conclusion, the use of LMPLA improved the efficacy of KM24b as preventive experimental vaccine against T. cruzi challenge; however, did not improve the efficacy of NGP Galalpha(1,3)Galbeta(1,4)GlcNAc-NH-HSA (3 atom-linker).
Notlar:
School code: 0459
Konu Başlığı:
Tüzel Kişi Ek Girişi:
Mevcut:*
Yer Numarası | Demirbaş Numarası | Shelf Location | Lokasyon / Statüsü / İade Tarihi |
---|---|---|---|
XX(693998.1) | 693998-1001 | Proquest E-Tez Koleksiyonu | Arıyor... |
On Order
Liste seç
Bunu varsayılan liste yap.
Öğeler başarıyla eklendi
Öğeler eklenirken hata oldu. Lütfen tekrar deneyiniz.
:
Select An Item
Data usage warning: You will receive one text message for each title you selected.
Standard text messaging rates apply.